Previous Close | 22.26 |
Open | 22.15 |
Bid | 22.32 x 1100 |
Ask | 23.00 x 900 |
Day's Range | 22.02 - 22.75 |
52 Week Range | 18.05 - 31.78 |
Volume | |
Avg. Volume | 1,023,118 |
Market Cap | 3.003B |
Beta (5Y Monthly) | 0.26 |
PE Ratio (TTM) | 6.25 |
EPS (TTM) | 3.60 |
Earnings Date | May 03, 2023 - May 08, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 50.14 |
For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived the
SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET. A live webcast of the panel can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archiv